Haselmeier Announces the CE Mark for JuniorSTAR? Half-Unit Insulin Pen
Haselmeier has announced the CE Mark of JuniorSTAR by Sanofi. JuniorSTAR is a new easy-to-use, half-unit insulin reusable pen that can be used with Lantus (insulin glargine), Apidra (insulin glulisine) or Insuman (recombinant human insulin).
Developed and manufactured by Haselmeier, JuniorSTAR is a light-weight reusable pen with a large dose display, single-step dial back without insulin leakage and delivers from 1 to 30 units per injection.
“Haselmeier is proud to partner with Sanofi on this important programme to develop and manufacture JuniorSTAR and we look forward to continuing our business relationship in the future,” said Frédéric Gabriel, General Manager of Haselmeier.
Director Project Management at Haselmeier, Sandra de Haan adds that “the excellent cooperation between Sanofi and Haselmeier project teams ensured announcement to the diabetes community at the recent EASD congress".
Half-unit dose increment pens provide flexibility to achieve target insulin doses especially in young patients with diabetes. JuniorSTAR has been tested by people with type 1 diabetes (6–18 years old), parents and nurses in a non-comparative survey with 167 insulin pen users from five European countries1:
• 81% of patients/parents and 86% of nurses agreed it is easy to carry on a daily basis, because of its light weight (~ 34 g)
• 98% of patients/parents and 94% of nurses agreed it is easy to read becasue of its large dose display and legible numbers
• 91% of patients/parents and 89% of nurses agreed that the dialling back was easy because of its single-step dial back without insulin leakage
• 93% of survey participants agreed on its ease of use.
JuniorSTAR meets the new ISO 11608-1:2012 standard and passed all requirements for robustness and dose accuracy. It is offered in three different colors (blue, red and silver), for flexibility and insulin differentiation.
JuniorSTAR is expected to be available in Europe and Canada throughout 2014.
1. D. Klonoff et al., "Evaluation of the JuniorSTAR half-unit insulin pen in young people with type 1 diabetes - user perspectives," European Endocrinology, 9(2), 82–85 (2013).
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation.
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field.
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke...
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA).
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors stateDoctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients.
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre...
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts.
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
Generate high-quality, engaged leads for your business, all year round
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
Your company’s profile boosted at all participating CPHI events
An easy-to-use platform with a detailed dashboard showing your leads and performance